BRPI0608573A2 - Composição farmacêutica, e, método para a preparação de uma composição farmacêutica. - Google Patents
Composição farmacêutica, e, método para a preparação de uma composição farmacêutica.Info
- Publication number
- BRPI0608573A2 BRPI0608573A2 BRPI0608573A BRPI0608573A BRPI0608573A2 BR PI0608573 A2 BRPI0608573 A2 BR PI0608573A2 BR PI0608573 A BRPI0608573 A BR PI0608573A BR PI0608573 A BRPI0608573 A BR PI0608573A BR PI0608573 A2 BRPI0608573 A2 BR PI0608573A2
- Authority
- BR
- Brazil
- Prior art keywords
- sirolimus
- pharmaceutical composition
- compositions
- expected
- preparing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
COMPOSIÇÃO FARMACÊUTICA, E, MÉTODO PARA A PREPARAÇÃO DE UMA COMPOSIÇÃO FARMACÊUTICA. A presente invenção diz respeito a composições farmacêuticas na forma particulada ou em formas de dosagem sólidas compreendendo sirolimus (rapamicina) e/ou derivados e/ou análogos deste. Composições da invenção apresentam urna biodisponibilidade aceitável de sirolimus e/ou um derivado e/ou um análogo deste. As composições farmacêuticas da invenção são projetadas para liberar sirolimus de urna maneira controlada, de forma tal que os níveis plasmáticos permaneçam na estreita janela terapêutica que existe para esta classe de substancias. Espera-se que um perfil de liberação lento, onde a concentração do pico foi reduzida sem perda significativa da biodisponibilidade, iuntamente com menos absorção variável, melhore a razão segurança/eficácia do medicamento. Além disso, espera-se que composições de acordo com a invenção fbrneçam um efeito do alimento reduzido significativo e uma liberação atrasada de sirolimus para reduzir o número de efeitos colaterais relacionados ao trato gastrintestinal.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200500344 | 2005-03-08 | ||
PCT/DK2006/000135 WO2006094507A1 (en) | 2005-03-08 | 2006-03-08 | Pharmaceutical compositions comprising sirolimus and/or an analogue thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0608573A2 true BRPI0608573A2 (pt) | 2017-07-25 |
Family
ID=36577478
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0608573A BRPI0608573A2 (pt) | 2005-03-08 | 2006-03-08 | Composição farmacêutica, e, método para a preparação de uma composição farmacêutica. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20080275076A1 (pt) |
EP (1) | EP1858511A1 (pt) |
JP (1) | JP2008532953A (pt) |
CN (1) | CN101137365A (pt) |
AU (1) | AU2006222409A1 (pt) |
BR (1) | BRPI0608573A2 (pt) |
CA (1) | CA2599758A1 (pt) |
MX (1) | MX2007010860A (pt) |
NO (1) | NO20075058L (pt) |
WO (1) | WO2006094507A1 (pt) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7700614B2 (en) * | 2005-12-14 | 2010-04-20 | Abbott Laboratories | One pot synthesis of tetrazole derivatives of rapamycin |
EP1952807A1 (en) * | 2007-01-24 | 2008-08-06 | LEK Pharmaceuticals D.D. | Sirolimus formulation |
TWI478712B (zh) * | 2008-09-30 | 2015-04-01 | Astellas Pharma Inc | 釋控性醫藥組成物 |
CA2937492C (en) | 2008-11-11 | 2019-08-13 | The Board Of Regents Of The University Of Texas System | Inhibition of mammalian target of rapamycin |
EP2470179B1 (en) | 2009-08-26 | 2017-11-29 | Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. | Sustained release delivery systems for the prevention and treatment of head and neck cancers |
US10391059B2 (en) | 2009-11-11 | 2019-08-27 | Rapamycin Holdings, Inc. | Oral rapamycin nanoparticle preparations and use |
US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
WO2011122523A1 (ja) * | 2010-03-29 | 2011-10-06 | アステラス製薬株式会社 | 放出制御医薬組成物 |
EP2554168B1 (en) | 2010-03-29 | 2018-01-24 | Astellas Pharma Inc. | Controlled release pharmaceutical composition |
US8632979B2 (en) * | 2010-11-22 | 2014-01-21 | Albert Einstein College Of Medicine Of Yeshiva University | Methods for determining agents that treat or prevent obesity and/or obesity related diseases and methods for treatment therewith |
CN102008437B (zh) * | 2010-11-23 | 2012-11-14 | 赵晨 | 一种雷帕霉素眼用微乳注射剂及其制备方法和应用 |
CN102138903B (zh) * | 2011-03-17 | 2012-12-12 | 苏州特瑞药业有限公司 | 一种依维莫司固体口服药物组合物 |
US9265815B2 (en) * | 2011-04-29 | 2016-02-23 | Selecta Biosciences, Inc. | Tolerogenic synthetic nanocarriers |
US8951996B2 (en) * | 2011-07-28 | 2015-02-10 | Lipocine Inc. | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
US8912215B2 (en) | 2011-12-13 | 2014-12-16 | Everon Biosciences, Inc. | Rapamycin composition |
NZ630435A (en) * | 2012-07-12 | 2016-11-25 | Abbvie Inc | Crystalline forms of an hcv inhibitor |
EP2968281B1 (en) | 2013-03-13 | 2020-08-05 | The Board of Regents of The University of Texas System | Mtor inhibitors for prevention of intestinal polyp growth |
ES2799185T3 (es) | 2013-03-13 | 2020-12-15 | Santen Pharmaceutical Co Ltd | Agente terapéutico para la disfunción meibomiana |
WO2014144346A1 (en) * | 2013-03-15 | 2014-09-18 | The Board Of Regents Of The University Of Texas System | Use of inhibitors of mtor to improve vascular functions in apoe4 carriers |
JP7028556B2 (ja) | 2013-05-03 | 2022-03-02 | セレクタ バイオサイエンシーズ インコーポレーテッド | 特定の薬力学的有効期間および免疫寛容の誘発のための抗原を有する免疫抑制剤の送達 |
CN104248636A (zh) * | 2013-06-28 | 2014-12-31 | 上海星泰医药科技有限公司 | 一种西罗莫司制剂及其制备方法 |
KR102256576B1 (ko) | 2013-10-08 | 2021-05-27 | 에이아이 테라퓨틱스, 인코포레이티드 | 림프관평활근종증의 치료를 위한 라파마이신 |
US20160317560A1 (en) * | 2013-11-07 | 2016-11-03 | The University Of North Carolina At Chapel Hill | Particles containing phospholipids or bioactive fatty acids and uses thereof |
US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
EP3104891A1 (en) | 2014-02-11 | 2016-12-21 | Lam Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
US10307371B2 (en) | 2014-02-11 | 2019-06-04 | AI Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
HUP1400075A2 (hu) * | 2014-02-14 | 2015-08-28 | Druggability Technologies Ip Holdco Jersey Ltd | Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói |
PL3125875T3 (pl) | 2014-04-04 | 2023-11-20 | AI Therapeutics, Inc. | Nadający się do inhalacji preparat rapamycyny do leczenia stanów związanych z wiekiem |
MX2017002933A (es) | 2014-09-07 | 2017-05-30 | Selecta Biosciences Inc | Metodos y composiciones para atenuar las respuestas inmunes del vector de transferencia anti-viral de edicion del gen. |
WO2016057712A1 (en) * | 2014-10-07 | 2016-04-14 | Lam Therapeutics, Inc. | An inhalable rapamycin formulation for the treatment of pulmonary hypertension |
EP3212194A4 (en) | 2014-10-29 | 2018-06-20 | University Of Maryland | Methods of treating age-related symptoms in mammals and compositions therefor |
MA40910A (fr) | 2014-11-07 | 2017-09-12 | Civitas Therapeutics Inc | Poudres de rapamycine pour administration pulmonaire |
WO2016130645A1 (en) | 2015-02-10 | 2016-08-18 | Lam Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
EP3297629A1 (en) | 2015-05-20 | 2018-03-28 | Novartis AG | Pharmaceutical combination of everolimus with dactolisib |
US20160374616A1 (en) * | 2015-06-24 | 2016-12-29 | Daqri, Llc | Electrode contact quality |
US20190290631A1 (en) * | 2016-05-27 | 2019-09-26 | Nippon Kayaku Kabushiki Kaisha | Pharmaceutical composition comprising rapamycin or derivative thereof |
EP3544608A1 (en) | 2016-11-23 | 2019-10-02 | Novartis AG | Methods of enhancing immune response with everolimus, dactolisib or both |
WO2018169811A1 (en) | 2017-03-11 | 2018-09-20 | Selecta Biosciences, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
US20190250208A1 (en) * | 2018-02-09 | 2019-08-15 | Qualcomm Incorporated | Apparatus and method for detecting damage to an integrated circuit |
US10596165B2 (en) | 2018-02-12 | 2020-03-24 | resTORbio, Inc. | Combination therapies |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6204243B1 (en) * | 1993-09-01 | 2001-03-20 | Novatis Ag | Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis |
IL111003A0 (en) * | 1993-09-30 | 1994-11-28 | American Home Prod | Multi-component oral rapamycin formulation |
BE1009856A5 (fr) * | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
CA2230748C (en) * | 1997-03-14 | 2010-08-03 | American Home Products Corporation | Rapamycin formulations for oral administration |
JP4570357B2 (ja) * | 2001-07-06 | 2010-10-27 | ライフサイクル ファーマ エー/エス | 制御された凝集 |
-
2006
- 2006-03-08 EP EP06706106A patent/EP1858511A1/en not_active Withdrawn
- 2006-03-08 US US11/885,992 patent/US20080275076A1/en not_active Abandoned
- 2006-03-08 AU AU2006222409A patent/AU2006222409A1/en not_active Abandoned
- 2006-03-08 CA CA002599758A patent/CA2599758A1/en not_active Abandoned
- 2006-03-08 CN CNA2006800074780A patent/CN101137365A/zh active Pending
- 2006-03-08 BR BRPI0608573A patent/BRPI0608573A2/pt not_active IP Right Cessation
- 2006-03-08 JP JP2008500047A patent/JP2008532953A/ja not_active Withdrawn
- 2006-03-08 WO PCT/DK2006/000135 patent/WO2006094507A1/en active Application Filing
- 2006-03-08 MX MX2007010860A patent/MX2007010860A/es not_active Application Discontinuation
-
2007
- 2007-10-08 NO NO20075058A patent/NO20075058L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US20080275076A1 (en) | 2008-11-06 |
AU2006222409A1 (en) | 2006-09-14 |
CN101137365A (zh) | 2008-03-05 |
CA2599758A1 (en) | 2006-09-14 |
WO2006094507A1 (en) | 2006-09-14 |
JP2008532953A (ja) | 2008-08-21 |
MX2007010860A (es) | 2007-11-12 |
EP1858511A1 (en) | 2007-11-28 |
NO20075058L (no) | 2007-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0608573A2 (pt) | Composição farmacêutica, e, método para a preparação de uma composição farmacêutica. | |
BR112015023922A2 (pt) | composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes | |
EA200802118A1 (ru) | Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях | |
NO20073722L (no) | Farmasoystiske sammensetniger omfattende bendamustin | |
BRPI0816320A2 (pt) | Composto, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto de combinação, e, processos para a preparação deu um composto, de uma formulação farmacêutica, e de um produto de combinação | |
NO20082088L (no) | Azetidiner som MEK-inhibitorer for behandling av proliferative sykdommer | |
NO20092737L (no) | Substituerte pyrazolo-kinazolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som kinase-inhibitorer | |
BRPI0508540A (pt) | composto, composição farmacêutica, e, uso de um composto | |
BRPI0713447A2 (pt) | composição forma de dosagem oral sólida, e, método para o tratamento de dor | |
BR112015010977A2 (pt) | derivado de piridina, sal farmaceuticamente aceitável do mesmo ou solvato do mesmo, pró-droga, composição farmacêutica, inibidor do urat1, agente para o tratamento ou prevenção de uma ou mais doenças, e, composto | |
NO20090887L (no) | Fremgangsmate for behandling og forebygging av mukositt | |
NO20082047L (no) | Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme | |
NO20091191L (no) | Fremgangsmater for behandling av kreft, innbefattende administrering av et vitamin D preparat og et ytterligere terapeutisk middel, og sammensetninger som inneholder de samme | |
CL2007003209A1 (es) | Composicion que comprende una vacuna de flavivirus vivos atenuados; composicion que comprende un producto farmaceutico derivado de virus o proteina; un metodo para la elaboracion de una composicion terapeutica que comprende liofilizar las composicion | |
NO20062432L (no) | Farmasoytiske formuleringer for baeremedierte transportstatiner og anvendelse derav | |
ATE494889T1 (de) | Pharmazeutische kombination mit 3- (3- dimethylamino-1-ethyl-2-methyl-propyl)-phenol und paracetamol | |
BRPI1007092B8 (pt) | Derivados de hidroxamato, uso dos derivados de hidroxamato, composições farmacêuticas e método de produção de derivados de hidroxamato | |
EP2142549A4 (en) | ADENOSINE DERIVATIVES, METHODS OF THEIR SYNTHESIS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES THEREOF CONTAINING THEM AS AN ACTIVE SUBSTANCE | |
BRPI1015539A2 (pt) | composições e métodos para tratamento de queimaduras | |
WO2009026473A3 (en) | Stabilized therapeutic compositions and formulations | |
NO20092763L (no) | Isosorbid mononitrat derivater for behandling av tarmlidelser | |
HRP20130695T1 (hr) | Adiponektin za lijeäśenje pluä†ne bolesti | |
EA200901201A1 (ru) | Применение композиции, содержащей формотерол и дипропионат беклометазона, для предотвращения и/или лечения обострения астмы | |
BR112014012277A2 (pt) | composição farmacêutica para tratamento de reações alérgicas | |
BR102012028120B8 (pt) | Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA. |
|
B11Z | Dismissal: petition dismissal - article 216, par 2 of industrial property law |
Free format text: REFERENTE A PETICAO 020070125593/RJ DE 06/09/2007. |
|
B06H | Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette] |
Free format text: O DESPACHO 6.7 DA RPI 2068 DE 24/08/2010 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0 |
|
B11M | Decision cancelled [chapter 11.13 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |